We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03061006
Recruitment Status : Completed
First Posted : February 23, 2017
Last Update Posted : September 2, 2021
Boehringer Ingelheim
Information provided by (Responsible Party):
Intermountain Health Care, Inc.

Brief Summary:
Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study. After written informed consent is obtained, subjects who meet eligibility criteria will be randomized 1:1 to 2 treatment arms: Group 1: Dabigatran etexilate (150 mg BID if CrCL > 30 mL/min, or 75 mg BID if CrCL > 15 to 30 mL/min or per USPI; and Group 2: Warfarin (Dose-adjusted (INR 2.0 - 3.0). Assessment of kidney function every 6 months will be done for Group 1. Standard warfarin follow-up and education, based upon system criteria, will be done for Group 2. All subjects will be followed for 24 months, and will be assessed at 1-week, then 3-, 6-, 12-, 18- and 24-months post-anticoagulation visits as well as other visits deem necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit following the week 1 visit, except at the 3-month visit when only one questionnaire will be administered. To determine brain volume and characteristic changes representative of micro-bleeding, the first 10 subjects in each treatment group who are willing and able to undergo the procedure will participate in a MRI sub-study. The cranial MRI will be done at baseline and at 24-months post-anticoagulation on this sub-group.

Condition or disease Intervention/treatment Phase
Dementia Cognition Disorders Cerebral Ischemic Events Drug: Dabigatran Etexilate Drug: Warfarin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 101 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial)
Actual Study Start Date : April 3, 2017
Actual Primary Completion Date : March 15, 2021
Actual Study Completion Date : March 15, 2021

Arm Intervention/treatment
Experimental: Dabigatran Etexilate
150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
Drug: Dabigatran Etexilate
150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL > 15 to 30 mL/min); Assessment of kidney function every 6 months.
Other Name: Pradaxa

Active Comparator: Warfarin
Dose-adjusted warfarin (INR: 2.0-3.0)
Drug: Warfarin
Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
Other Name: Coumadin

Primary Outcome Measures :
  1. Incident dementia determined by a formal diagnosis of dementia by a neurologist [ Time Frame: 24 months ]
    Incident dementia will be determined by a formal diagnosis of dementia by a neurologist

  2. Moderate decline in cognitive function based on results of the Alzheimer's Disease Assessment Scale and the Disability Assessment for Dementia. [ Time Frame: 24 months ]
    Determined by measuring the change from baseline to study conclusion on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70, and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100, and higher scores indicating less impairment). An increase in ADAS-cog11 of >30% is considered significant for moderate cognitive decline. In subjects that score <50% on the DAD, there is a direct correlation with global deterioration scales and scores. Subjects with a 30% decrease in DAD score or those with a score <50% will be considered to have moderate cognitive decline. These scores will be aggregated and if a patient meets either one of the cognitive decline definitions they will be deemed positive for cognitive impairment.

Secondary Outcome Measures :
  1. Stroke or Transient ischemic attack (TIA), intracranial bleed [ Time Frame: 24 months ]
  2. Changes from baseline scores on the mini-mental status evaluation and the Hachinski Ischemic Scale. [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female >65 years of age.
  2. Non-valvular atrial fibrillation documented by electrocardiogram, ambulatory event monitor, or telemetry within 12 months of enrollment.
  3. Moderate risk of thromboembolism based upon a CHADS score or CHADS2 Vasc score of ≥2.
  4. Ability to complete a mini-mental status evaluation.
  5. Ability to independently comprehend and complete a quality of life and dementia questionnaires.
  6. Ability to provide informed consent for study participation.
  7. Willing and able to comply with the prescribed follow-up tests and schedule of evaluations.

Exclusion Criteria:

  1. Inability to take an anticoagulant due to known or perceived bleeding risk.
  2. Known coagulopathy that may impact the choice, duration, efficacy and safety of anticoagulation therapy.
  3. Atrial Fibrillation in the setting of valvular heart disease. Valvular heart disease defined as any surgical valve, mitral stenosis, or moderate-severe valvular heart disease.
  4. Severe renal dysfunction, defined as a creatinine clearance rate <15 mL/min (documented within the last 3 months).
  5. History of any form of dementia.
  6. A life expectancy less than 24 months.
  7. Inability to comply with the follow-up schedule.
  8. Current participation in a clinical investigation that includes an active pharmacologic treatment arm.
  9. An upper age limit not to be used if participation inclusion criteria are met.
  10. Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.
  11. Other conditions that in the opinion of the Principal Investigator(s) may increase risk to the subject and/or compromise the quality of the clinical trial.
  12. Concurrent pharmacologic treatment that is required to treat a condition long-term in which concurrent use of dabigatran etexilate is contraindicated.
  13. Treatment with any anticoagulant drug for stroke prevention for more than 30 days.

    • Aspirin and P2Y12 inhibitors (e.g. clopidogrel (Plavix), or prasugrel (Effient)) are not considered anticoagulant drugs.
    • If the subject has received any anticoagulant drug for stroke prevention for less than 30 days, the Principal Investigator(s) or a Co-Investigator will decide whether or not the subject is eligible for this study
  14. The Principal Investigator(s) determine(s) that the subject is not eligible for participation in this research study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03061006

Layout table for location information
United States, Utah
Intermountain Heart Institute
Murray, Utah, United States, 84143
Sponsors and Collaborators
Intermountain Health Care, Inc.
Boehringer Ingelheim
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Intermountain Health Care, Inc.
ClinicalTrials.gov Identifier: NCT03061006    
Other Study ID Numbers: 1050164
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: September 2, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Cognitive Dysfunction
Cognition Disorders
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action